Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Respir Res ; 20(1): 10, 2019 Jan 15.
Article in English | MEDLINE | ID: mdl-30646908

ABSTRACT

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive and irreversible respiratory failure. Non-invasive markers of disease activity are essential for prognosis and evaluation of early response to anti-fibrotic treatments. OBJECTIVES: The aims of this study were to determine whether fluorodeoxyglucose ([18F]-FDG) lung uptake is reduced after initiation of pirfenidone or nintedanib and to assess its possible use as a prognostic factor. METHODS: [18F]-FDG PET/CT was performed in IPF patients and in a murine model of pulmonary fibrosis. PET/CTs were performed at day 8 and day 15 post-instillation of bleomycin in pirfenidone- or vehicule-treated mice. In IPF patients, PET-CT was performed before and 3 months after the initiation of pirfenidone or nintedanib. RESULTS: In bleomycin-treated mice, pirfenidone significantly reduced the [18F]-FDG uptake compared to vehicule-treated mice at day 15 (p < 0.001), whereas no difference was observed at day 8 after bleomycin administration. In IPF patients, [18F]-FDG lung uptake before and after 3 months of treatment by nintedanib (n = 11) or pirfenidone (n = 14) showed no significant difference regardless the antifibrotic treatment. Moreover, no difference was noticed between patients with progressive or non-progressive disease at one year of follow up. CONCLUSIONS: Pirfenidone significantly reduces the lung [18F]-FDG uptake during the fibrotic phase in a mouse model of IPF. However, these preclinical data were not confirmed in IPF patients 3 months after the initiation of antifibrotic therapy. [18F]-FDG seems therefore not useful in clinical practice to assess the early response of IPF patients to nintedanib or pirfenidone.


Subject(s)
Fluorodeoxyglucose F18 , Idiopathic Pulmonary Fibrosis/diagnostic imaging , Idiopathic Pulmonary Fibrosis/drug therapy , Indoles/therapeutic use , Positron Emission Tomography Computed Tomography/methods , Pyridones/therapeutic use , Aged , Animals , Antineoplastic Agents/therapeutic use , Female , Fibrosis , Humans , Idiopathic Pulmonary Fibrosis/metabolism , Male , Mice , Mice, Inbred C57BL , Middle Aged , Prospective Studies
2.
Oncogene ; 37(9): 1237-1250, 2018 03.
Article in English | MEDLINE | ID: mdl-29242606

ABSTRACT

Cancer research is increasingly dependent of patient-derived xenograft model (PDX). However, a major point of concern regarding the PDX model remains the replacement of the human stroma with murine counterpart. In the present work we aimed at clarifying the significance of the human-to-murine stromal replacement for the fidelity of colorectal cancer (CRC) and liver metastasis (CRC-LM) PDX model. We have conducted a comparative metabolic analysis between 6 patient tumors and corresponding PDX across 4 generations. Metabolic signatures of cancer cells and stroma were measured separately by MALDI-imaging, while metabolite changes in entire tumors were quantified using mass spectrometry approach. Measurement of glucose metabolism was also conducted in vivo using [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET). In CRC/CRC-LM PDX model, human stroma was entirely replaced at the second generation. Despite this change, MALDI-imaging demonstrated that the metabolic profiles of both stromal and cancer cells remained stable for at least four generations in comparison to the original patient material. On the tumor level, profiles of 86 water-soluble metabolites as well as 93 lipid mediators underlined the functional stability of the PDX model. In vivo PET measurement of glucose uptake (reflecting tumor glucose metabolism) supported the ex vivo observations. Our data show for the first time that CRC/CRC-LM PDX model maintains the functional stability at the metabolic level despite the early replacement of the human stroma by murine cells. The findings demonstrate that human cancer cells actively educate murine stromal cells during PDX development to adopt the human-like phenotype.


Subject(s)
Cancer-Associated Fibroblasts/metabolism , Colorectal Neoplasms/metabolism , Disease Models, Animal , Glucose/metabolism , Liver Neoplasms/metabolism , Metabolome , Stromal Cells/metabolism , Animals , Cancer-Associated Fibroblasts/pathology , Cohort Studies , Colorectal Neoplasms/pathology , Female , Humans , Liver Neoplasms/secondary , Male , Mice , Mice, Inbred NOD , Mice, SCID , Phenotype , Stromal Cells/pathology , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
3.
Int J Mol Sci ; 18(1)2017 Jan 21.
Article in English | MEDLINE | ID: mdl-28117708

ABSTRACT

Cancer cells generally rely on aerobic glycolysis as a major source of energy. Methylglyoxal (MG), a dicarbonyl compound that is produced as a side product during glycolysis, is highly reactive and induces the formation of advanced glycation end-products that are implicated in several pathologies including cancer. All mammalian cells have an enzymatic defense against MG composed by glyoxalases GLO1 and GLO2 that converts MG to d-lactate. Colorectal cancer (CRC) is one of the most frequently occurring cancers with high morbidity and mortality. In this study, we used immunohistochemistry to examine the level of MG protein adducts, in a series of 102 CRC human tumors divided into four clinical stages. We consistently detected a high level of MG adducts and low GLO1 activity in high stage tumors compared to low stage ones suggesting a pro-tumor role for dicarbonyl stress. Accordingly, GLO1 depletion in CRC cells promoted tumor growth in vivo that was efficiently reversed using carnosine, a potent MG scavenger. Our study represents the first demonstration that MG adducts accumulation is a consistent feature of high stage CRC tumors. Our data point to MG production and detoxification levels as an important molecular link between exacerbated glycolytic activity and CRC progression.


Subject(s)
Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Pyruvaldehyde/pharmacology , Stress, Physiological/drug effects , Adult , Aged , Animals , Carnosine/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Chickens , Cohort Studies , Fluorodeoxyglucose F18 , Glycolysis/drug effects , Humans , Lactoylglutathione Lyase/metabolism , Middle Aged , Neoplasm Staging , Positron-Emission Tomography , Pyrimidines/pharmacology
4.
J Nucl Med ; 56(1): 127-32, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25537989

ABSTRACT

UNLABELLED: Idiopathic pulmonary fibrosis is characterized by a progressive and irreversible respiratory failure. Validated noninvasive methods able to assess disease activity are essential for prognostic purposes as well as for the evaluation of emerging antifibrotic treatments. METHODS: C57BL/6 mice were used in a murine model of pulmonary fibrosis induced by an intratracheal instillation of bleomycin (control mice were instilled with a saline solution). At different times after instillation, PET/CT with (18)F-FDG- or (18)F-4-fluorobenzamido-N-ethylamino-maleimide ((18)F-FBEM)-labeled leukocytes was performed to assess metabolic activity and leukocyte recruitment, respectively. RESULTS: In bleomycin-treated mice, a higher metabolic activity was measured on (18)F-FDG PET/CT scans from day 7 to day 24 after instillation, with a peak of activity measured at day 14. Of note, lung mean standardized uptake values correlated with bleomycin doses, histologic score of fibrosis, lung hydroxyproline content, and weight loss. Moreover, during the inflammatory phase of the model (day 7), but not the fibrotic phase (day 23), bleomycin-treated mice presented with an enhanced leukocyte recruitment as assessed by (18)F-FBEM-labeled leukocyte PET/CT. Autoradiographic analysis of lung sections and CD45 immunostaining confirm the higher and early recruitment of leukocytes in bleomycin-treated mice, compared with control mice. CONCLUSION: (18)F-FDG- and (18)F-FBEM-labeled leukocyte PET/CT enable monitoring of metabolic activity and leukocyte recruitment in a mouse model of pulmonary fibrosis. Implications for preclinical evaluation of antifibrotic therapy are expected.


Subject(s)
Fluorodeoxyglucose F18 , Leukocytes/immunology , Leukocytes/metabolism , Maleimides , Positron-Emission Tomography , Pulmonary Fibrosis/metabolism , Tomography, X-Ray Computed , Animals , Biological Transport/drug effects , Bleomycin/adverse effects , Body Weight/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Fibrosis , Fluorodeoxyglucose F18/metabolism , Leukocytes/diagnostic imaging , Lung/drug effects , Lung/immunology , Maleimides/metabolism , Mice , Pulmonary Fibrosis/diagnostic imaging , Pulmonary Fibrosis/pathology , Staining and Labeling
5.
J Exp Med ; 210(9): 1675-84, 2013 Aug 26.
Article in English | MEDLINE | ID: mdl-23940256

ABSTRACT

Interleukin (IL) 12 and IL23 are two related heterodimeric cytokines produced by antigen-presenting cells. The balance between these two cytokines plays a crucial role in the control of Th1/Th17 responses and autoimmune inflammation. Most studies focused on their transcriptional regulation. Herein, we explored the role of the adenine and uridine-rich element (ARE)-binding protein tristetraprolin (TTP) in influencing mRNA stability of IL12p35, IL12/23p40, and IL23p19 subunits. LPS-stimulated bone marrow-derived dendritic cells (BMDCs) from TTP(-/-) mice produced normal levels of IL12/23p40. Production of IL12p70 was modestly increased in these conditions. In contrast, we observed a strong impact of TTP on IL23 production and IL23p19 mRNA stability through several AREs in the 3' untranslated region. TTP(-/-) mice spontaneously develop an inflammatory syndrome characterized by cachexia, myeloid hyperplasia, dermatitis, and erosive arthritis. We observed IL23p19 expression within skin lesions associated with exacerbated IL17A and IL22 production by infiltrating γδ T cells and draining lymph node CD4 T cells. We demonstrate that the clinical and immunological parameters associated with TTP deficiency were completely dependent on the IL23-IL17A axis. We conclude that tight control of IL23 mRNA stability by TTP is critical to avoid severe inflammation.


Subject(s)
Inflammation/genetics , Inflammation/prevention & control , Interleukin-23/genetics , RNA Stability/genetics , Tristetraprolin/metabolism , 3' Untranslated Regions/genetics , AU Rich Elements/genetics , Animals , Bone Diseases, Metabolic/diagnostic imaging , Bone Diseases, Metabolic/genetics , Bone Diseases, Metabolic/pathology , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , Bone Remodeling/drug effects , Bone Remodeling/genetics , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Dendritic Cells/pathology , HEK293 Cells , Humans , Interleukin-17/metabolism , Interleukin-23/biosynthesis , Interleukin-23 Subunit p19/metabolism , Interleukins/metabolism , Lipopolysaccharides/pharmacology , Mice , RNA Stability/drug effects , Radiography , Syndrome , Tristetraprolin/deficiency , Interleukin-22
SELECTION OF CITATIONS
SEARCH DETAIL
...